Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph F Merola

Showing results (181-190 of 393) with videos related to

Pageof 40
Sort By:
Journal of the European Academy of Dermatology and Venereology : JEADV|July 24, 2025
Improvement and maintenance of clinical outcome assessments in atopic dermatitis with amlitelimabAndrew Blauvelt, Raj Chovatiya, Joseph F Merola, et al.
BMC Ophthalmology|April 3, 2026
Atopic dermatitis and ocular surface disorders: a United States claims-based cross-sectional studyPenny Asbell, Esen K Akpek, Joseph F Merola, et al.
Journal of Psoriasis and Psoriatic Arthritis|May 5, 2026
Safety of IL-17A Inhibitors in Patients With Moderate to Severe Psoriasis in a US Claims Data-Based Cohort StudyMaria C Schneeweiss, Joseph F Merola, Yinzhu Jin, et al.
Dermatology and Therapy|July 11, 2023
Ixekizumab Real-World Effectiveness at 24 Weeks in Patients with Psoriasis: Data from the United States Taltz Customer Support ProgramAlice B Gottlieb, Russel Burge, William N Malatestinic, et al.
Arthritis Care & Research|August 15, 2017
Patterns of Systemic Treatment for Psoriatic Arthritis in the US: 2004-2015Moa P Lee, Joyce Lii, Yinzhu Jin, et al.
Dermatology and Therapy|July 14, 2021
Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM), a Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Data from the BE VIVID and BE READY Phase 3 TrialsRichard B Warren, Alice B Gottlieb, Joseph F Merola, et al.
Journal of Drugs in Dermatology : JDD|March 17, 2017
The International Dermatology Outcome Measures (IDEOM) Initiative: A Review and UpdateScott A Elman, Joseph F Merola, April W Armstrong, et al.
The Journal of Dermatological Treatment|March 8, 2021
Clinical implications and predictive values of early PASI responses to tildrakizumab in patients with moderate-to-severe plaque psoriasisSteven R Feldman, Joseph F Merola, David M Pariser, et al.
Journal of the American Academy of Dermatology|August 21, 2023
Joint pain in patients with atopic dermatitis receiving treatment with dupilumab: A US nationwide cohort studyMaria C Schneeweiss, Richard Wyss, Sebastian Schneeweiss, et al.
Dermatology and Therapy|May 14, 2023
Patient and Physician Perceptions of Psoriatic Disease in the United States: Results from the UPLIFT SurveyJoseph F Merola, Alexis Ogdie, Alice B Gottlieb, et al.
Pageof 40

Showing results (181-190 of 393) with videos related to

Sort By:
Pageof 40
Journal of the European Academy of Dermatology and Venereology : JEADV|July 24, 2025
Improvement and maintenance of clinical outcome assessments in atopic dermatitis with amlitelimabAndrew Blauvelt, Raj Chovatiya, Joseph F Merola, et al.
BMC Ophthalmology|April 3, 2026
Atopic dermatitis and ocular surface disorders: a United States claims-based cross-sectional studyPenny Asbell, Esen K Akpek, Joseph F Merola, et al.
Journal of Psoriasis and Psoriatic Arthritis|May 5, 2026
Safety of IL-17A Inhibitors in Patients With Moderate to Severe Psoriasis in a US Claims Data-Based Cohort StudyMaria C Schneeweiss, Joseph F Merola, Yinzhu Jin, et al.
Dermatology and Therapy|July 11, 2023
Ixekizumab Real-World Effectiveness at 24 Weeks in Patients with Psoriasis: Data from the United States Taltz Customer Support ProgramAlice B Gottlieb, Russel Burge, William N Malatestinic, et al.
Arthritis Care & Research|August 15, 2017
Patterns of Systemic Treatment for Psoriatic Arthritis in the US: 2004-2015Moa P Lee, Joyce Lii, Yinzhu Jin, et al.
Dermatology and Therapy|July 14, 2021
Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM), a Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Data from the BE VIVID and BE READY Phase 3 TrialsRichard B Warren, Alice B Gottlieb, Joseph F Merola, et al.
Journal of Drugs in Dermatology : JDD|March 17, 2017
The International Dermatology Outcome Measures (IDEOM) Initiative: A Review and UpdateScott A Elman, Joseph F Merola, April W Armstrong, et al.
The Journal of Dermatological Treatment|March 8, 2021
Clinical implications and predictive values of early PASI responses to tildrakizumab in patients with moderate-to-severe plaque psoriasisSteven R Feldman, Joseph F Merola, David M Pariser, et al.
Journal of the American Academy of Dermatology|August 21, 2023
Joint pain in patients with atopic dermatitis receiving treatment with dupilumab: A US nationwide cohort studyMaria C Schneeweiss, Richard Wyss, Sebastian Schneeweiss, et al.
Dermatology and Therapy|May 14, 2023
Patient and Physician Perceptions of Psoriatic Disease in the United States: Results from the UPLIFT SurveyJoseph F Merola, Alexis Ogdie, Alice B Gottlieb, et al.
Pageof 40